Background-Heart transplant centers are generally considered "centers of excellence" for heart failure care. However, their overall performance has not previously been evaluated in a broad population of elderly patients with heart failure, many of whom are not transplant candidates. Methods and Results-We identified Ͼ1 million elderly Medicare beneficiaries who were hospitalized for heart failure between 2004 and 2006 at Ͼ4500 hospitals. We calculated 30-day risk-standardized mortality rates and standardized mortality ratios as well as 30-day risk-standardized readmission rates and standardized readmission ratios at heart transplant centers and non-heart transplant hospitals using risk-standardization models that the Centers for Medicare & Medicaid Services uses for public reporting. The 30-day risk-standardized mortality rates were lower at heart transplant centers than non-heart transplant hospitals nationally (10.6% versus 11.5%, PϽ0.001) but were similar at peer institutions offering coronary artery bypass grafting within the same geographical region (10.6% versus 10.6%, Pϭ0.96). The mean standardized mortality ratio for heart transplant centers was 0.9 (SD, 0.1; range, 0.7 to 1.3). No differences were noted in 30-day risk-standardized readmission rates between heart transplant centers and non-heart transplant hospitals nationally (23.6% versus 23.8%, Pϭ0.55). The mean standardized readmission ratio for heart transplant centers was 1.0 (SD, 0.1; range, 0.8 to 1.2). Conclusions-In elderly Medicare patients with heart failure, heart transplant centers have lower 30-day risk-standardized mortality rates than non-heart transplant hospitals nationally; however, this difference is not present in comparison with peer institutions or for 30-day risk-standardized readmission rates. (Circ Heart Fail. 2010;3:244-252.) 
S pecialist-directed care can improve outcomes across a wide range of medical conditions, including heart failure (HF). [1] [2] [3] [4] Hospitals performing heart transplants require dedicated infrastructure to evaluate and treat the sickest patients with HF and, in many ways, represent the ultimate specialistdirected care for this condition. However, HF outcomes at heart transplant centers have not been previously reported across a broad population of elderly patients, most of whom are not transplant candidates.
Clinical Perspective on p 252
Elderly patients who are hospitalized for HF have a high risk for death and suffer frequent readmissions after discharge, 5 and the risk for these outcomes varies markedly across hospitals. 1,6 -8 This observation is not entirely explained by patient characteristics, 1,6 -8 but little is known about the hospital-level factors that contribute to outcomes in the elderly HF population. It is plausible that the expertise at heart transplant centers improves outcomes for patients with HF hospitalized there, even those not eligible for transplantation. If this is the case, adopting some of the related processes of care at the much larger number of nontransplant hospitals might improve HF outcomes in elderly patients.
Accordingly, we used recently developed and validated risk-adjustment models to assess short-term HF outcomes in Medicare patients with HF hospitalized at heart transplant centers. We hypothesized that heart transplant centers would have lower risk-standardized 30-day mortality and readmission rates than hospitals that did not perform transplantation.
Medicare & Medicaid Services (CMS). These files included patientlevel demographic information, principal and secondary International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) diagnosis codes, and procedure codes on each hospitalization for the Medicare population. The study population included Medicare patients aged 65 years or older hospitalized with a principal discharge diagnosis of HF by ICD-9-CM diagnostic codes 402.01, 402. 11, 402.91, 404.01, 404.03, 404.11, 404.13, 404.91, 404 .93, or 428.xx.
We included discharges for patients enrolled in Medicare fee-forservice for at least 1 year because we used 12 months of previous utilization data to obtain information on comorbidities (see below). We excluded all discharges in patients who were discharged alive, not against medical advice, and within the first day of admission because we deemed these patients unlikely to have had truly decompensated HF (6% of total discharges for mortality cohort). Because we sought to focus on outcomes in "routine" patients with HF, we also excluded discharges for patients with a history of heart transplantation (ICD-9-CM procedure code 37.51) or mechanical circulatory support (ICD-9-CM procedure codes 37.52 to 37.54 and 37.62 to 37.68) (nϭ799 for the mortality analysis; nϭ1110 for the readmission analysis). We also excluded discharges from hospitals with 10 or fewer HF cases during the study period (nϭ1050 for the mortality analysis; nϭ823 for the readmission analysis).
By using publicly available data from the United Network of Organ Sharing, we identified 110 heart transplant centers that operated during the study period, including 14 small-volume (Ͻ10 transplants per year) heart transplant programs that were not approved by Medicare for heart transplant-related care but provided inpatient services for elderly Medicare patients with HF. We included these facilities because we judged them likely to have HF-related infrastructure similar to that at other heart transplant centers. We then identified all other non-heart transplant centers that cared for Medicare patients with HF during the study period. These were further stratified into nonpeer or peer institutions, with the latter defined as those with Ն300 beds and providing coronary artery bypass grafting (CABG).
For hospitalizations that involved interhospital transfer during an admission, we linked both hospitalizations into a single episode of care. For analyses related to mortality, outcomes were attributed to the initial admitting hospital; for analyses related to readmission, outcomes were attributed to the discharging hospital. In all cases, comorbidities were identified from data collected at the initial admitting hospital to avoid classifying in-hospital complications as comorbidities. For analyses related to mortality, if a patient had multiple HF hospitalizations within a single calendar year, 1 admission was randomly selected for the analysis. For readmission analyses, 1 discharge was randomly selected if the multiple HF hospitalizations occurred within a 30-day period and at the same hospital. This selection process led to different sample sizes between mortality and readmission (Tables 1 and 2) .
Outcome Variables and Risk-Standardization Models
Our primary outcomes were (1) all-cause mortality within 30 days from the date of the index HF admission and (2) all-cause hospital readmission within 30 days of the date of discharge from the index HF hospitalization for in-hospital survivors. For each outcome, separate study populations were constructed as described previously here. We used risk-standardization models that CMS currently uses for public reporting. Details have been previously published of the mortality 6 and readmission 7 risk standardization models. In summary, they are 2-level (patient and hospital) hierarchical random intercept models with patient characteristics as fixed effects at the patient level and random effects at the hospital level. No hospital characteristics were adjusted for random effects. 9 Importantly, these administrative data-based models perform well compared with models that use abstracted clinical chart data and have been endorsed by the National Quality Forum.
In brief, the risk-standardization models used patient-level administrative data in 2 demographic, 12 cardiovascular, and 29 comorbidity categories (Tables 1 and 2) obtained from Medicare Part A (ie, inpatient and hospital outpatient data) and B (ie, physician office outpatient data) files. These files include facility claims for inpatient care, ambulatory surgery, surgical or diagnostic procedures, and outpatient provider encounters. We used data on comorbidities from the index admission and utilization over the 12 months before the index admission to adjust for patient-specific risk. We obtained mortality data through the Medicare enrollment database.
Statistical Analysis
We compared baseline characteristics of patients by hospital typeheart transplant centers and non-heart transplant hospitals (including both nonpeer and peer institutions)-using 2 tests for categorical variables and ANOVA for continuous variables. By using data from all hospitals included in this study, we then calculated a 30-day standardized mortality ratio (SMR) for each hospital using hierarchical generalized linear models. 6 This technique accounts for patient characteristics and addresses the potential effects of patient clustering within hospitals. The SMR was calculated as the predicted mortality in each hospital, given its patient mix and estimated hospital-specific effect, divided by the expected mortality in that hospital, given the same patient mix and the average hospitalspecific effect. We used a bootstrapping algorithm within each institution to generate the 95% CI estimates of SMRs and their variances. To investigate hospital performance at heart transplant centers and nontransplant hospitals, each hospital was categorized on the basis of the 95% CI estimates of the SMRs into 1 of the following 3 groups: predicted mortality significantly better than expected mortality (ie, SMR significantly Ͻ1.0), predicted mortality no different than expected, or predicted mortality significantly worse than expected (ie, SMR significantly Ͼ1.0).
We calculated hospital-specific risk-standardized mortality rates (RSMRs) by multiplying each hospital's SMR by the national unadjusted rate. This form of indirect standardization allowed for assessments of overall quality in patients with HF at a hospital for the type of patients it treats, although direct hospital-to-hospital comparisons may be limited. 10 To further examine hospital performance at heart transplant and non-heart transplant hospitals nationwide, we categorized each hospital based on its RSMR into 1 of the following 3 groups: RSMRs below the 25th percentile, RSMRs between the 25th and 75th percentiles, and RSMRs above the 75th percentile. We then calculated the numbers of heart transplant and non-heart transplant hospitals within these 3 categories. For non-heart transplant hospitals, we separately calculated the numbers of nonpeer and peer institutions (as defined previously here) within each category. To further account for potential differences in patients across healthcare markets, we repeated these analyses after limiting the study population to patients at non-heart transplant hospitals that were located in the same hospital referral regions (HRRs) as a heart transplant center according to the Dartmouth Atlas of Health Care.
In the same manner, 30-day standard readmission ratios (SRRs) and risk-standardized readmission rates (RSRRs) were calculated for each hospital. We again categorized hospitals based on their SRR (significantly lower than expected, as expected, or significantly worse than expected) and RSRR (Ͻ25th percentile, 25th to 75th percentile, and Ͼ75th percentile). We conducted all analyses using SAS statistical software version 9.1.3.
Results
Between 2004 and 2006, we identified 1 318 899 discharges in Medicare patients with HF at 4570 hospitals in our study sample for assessing 30-day mortality and 1 610 803 discharges in Medicare patients with HF at 4607 hospitals in our study sample for assessing 30-day readmission rates. Among the study sample for 30-day mortality, 73 778 (5.6%) patients were admitted at 110 heart transplant centers, 289 710 (22.0%) were admitted at peer institutions with CABG, and 955 411 (72.4%) were admitted at nonpeer institutions. This pattern of admission across hospital types was similar in the study sample for 30-day readmission rates.
For the study samples examining 30-day mortality and readmission, baseline patient characteristics found in each hospital type are summarized in Tables 1 and 2 . In general, patients admitted at heart transplant centers were younger, more likely to be male gender, and had higher prevalence of previous heart disease than those at nontransplant hospitals. There was also a higher prevalence of cardiopulmonary respiratory failure or shock and renal failure in the heart transplant center cohort but a lower prevalence of chronic obstructive pulmonary disease, pneumonia, and dementia (Tables 1 and 2) . Patients admitted to peer institutions with CABG were more similar to those at heart transplant centers but still had slightly lower prevalence of previous heart disease, shock, and renal failure (data available from authors by request).
The observed 30-day mortality rates were 9.9% versus 11.5% (PϽ0.001), respectively, for Medicare patients with HF at heart transplant centers compared with those at nonheart transplant hospitals nationally. After adjustment for patient differences and hospital-level effects, the 30-day RSMRs remained significantly lower at heart transplant centers (10.6% versus 11.5%; PϽ0.001). When heart transplant centers were compared with peer institutions with CABG nationally, RSMRs remained significantly lower at heart transplant centers (10.6% versus 11.2%; Pϭ0.015). However, no differences in RSMRs were noted when heart transplant centers were compared with peer institutions with CABG within the same HRRs (10.6% versus 10.6%; Pϭ0.96). These findings are summarized in Table 3 . The percentage of each hospital type within RSMR categories (Ͻ25th percentile, between the 25th and 75th percentiles, and Ͼ75th percentile) is shown in Figure 1 .
Inspection of the SMRs for heart transplant centers revealed 25 institutions (22.7%) with SMRs significantly lower than the average expected mortality ratio for all hospitals (defined by 95% CIs with an upper limit excluding 1.0). Of the remaining heart transplant centers, 2 (1.8%) had SMRs significantly Ͼ1.0. The mean SMR for heart transplant centers was 0.9 (SD, 0.1; range, 0.7 to 1.3) [ Figure 2A ]. In comparison, 197 (4.4%) hospitals without heart transplantation had SMRs significantly Ͻ1.0, and 187 (4.2%) had SMRs significantly Ͼ1.0. The mean SMR for non-heart 
Hummel et al
Medicare HF Outcomes at Transplant Centers transplant hospitals was 1.01 (SD, 0.1; range, 0.5 to 1.7).
In the subset of peer institutions with CABG, 110 (11.2%) had SMRs significantly Ͻ1.0, and 85 (8.6%) had SMRs significantly Ͼ1.0.
In contrast to the these findings, observed 30-day readmission rates in Medicare patients with HF were not different between heart transplant centers and other nontransplant hospitals nationally (23.8% versus 23.8%; Pϭ0.65). After adjustment for patient differences and hospital-level effects, 30-day RSRRs remained similar between heart transplant centers and other hospitals (23.6% versus 23.8%; Pϭ0.55).
These findings are summarized in Table 4 . The percentage of each hospital type within RSRR categories (Ͻ25th percentile, between the 25th and 75th percentiles, and Ͼ75th percentile) is shown in Figure 3 .
Inspection of the SRRs for heart transplant centers revealed 18 (16.4%) hospitals with SRRs significantly lower than the average expected readmission ratio for all hospitals (defined by 95% CIs with an upper limit excluding 1.0). Of the remaining heart transplant centers, 16 (14.5%) had SRRs significantly Ͼ1.0. The mean SRR for heart transplant centers was 1.0 (SD, 0.1; range, 0.8 and 1.2) [ Figure 2B ]. In 
Discussion
Across a broad population of elderly Medicare patients with HF, we found that heart transplant centers had lower 30-day mortality rates than non-heart transplant hospitals nationally. This difference diminished after adjusting for patient characteristics and between-hospital variance across facilities. We noted no significant differences in 30-day risk-adjusted mortality between heart transplant centers and peer institutions providing CABG surgery in the same geographic area. Finally, 30-day risk-adjusted readmission rates were similar in Medicare patients with HF discharged from heart transplant centers and nontransplant hospitals. Within 30 days of hospital discharge for HF, 10% to 15% of elderly Medicare patients are readmitted to an acute care hospital, and 10% have died. 5 In our national sample of elderly Medicare patients with HF, we observed large between-hospital variations in 30-day RSMRs and RSRRs. Previous work by our group 6 and others 11, 12 has suggested that much of this variation is due to hospital-level characteristics rather than to patient characteristics or guideline adherence. Despite the lack of clinical trial evidence guiding the management of acutely decompensated HF, 13 a significant number of short-term deaths and rehospitalizations seem to be preventable. 14, 15 Understanding the hospital-level factors that contribute to early mortality and readmission is critical to improving outcomes in the elderly HF population.
The main findings of our study are somewhat unexpected. Heart transplant centers are generally considered "centers of excellence" for HF care because of the dedicated infrastructure needed to evaluate and treat complex and often critically ill patients with HF. We anticipated that the expertise present within successful heart transplant programs also would translate into better short-term outcomes in the general elderly HF population. Indeed, we did find lower 30-day mortality rates at heart transplant centers compared with all nontransplant hospitals. However, large, comparably resourced peer insti-tutions offering CABG surgery in the same geographic area had similar mortality outcomes to heart transplant centers. This finding suggests that the lower mortality rates in elderly Medicare patients with HF at heart transplant centers are unrelated to the presence of a transplant program and may be due to more traditional hospital-level factors. These characteristics could include better adherence to guideline-based performance measures, 16 higher hospital HF case volumes, 17 and increased likelihood of cardiologist-directed HF care, 4, 18 none of which are specific to heart transplant centers.
When we evaluated 30-day readmission rates, the results suggested even more equivalence between heart transplant centers and non-heart transplant hospitals perhaps because short-term hospital readmission in elderly patients with HF is often multifactorial and may depend, in part, on issues that are only indirectly related to disease severity or inpatient HF management. 14, 19, 20 The administrative risk-standardization model that we used for 30-day readmission is less predictive than that for 30-day mortality, 6,7 which could limit the ability of heart transplant centers to demonstrate improved readmission outcomes. Nonetheless, the overlap of the point estimates for SRR and RSRR at heart transplant centers and nontransplant hospitals is striking.
Transplant-eligible patients with HF are generally younger and have fewer comorbidities than the population we studied. Accordingly, these patients may have different predictors of outcomes or responses to interventions. However, it is likely that heart transplant centers use specific resources in this group that could potentially benefit elderly patients with HF, who often present with multiple medical comorbidities, polypharmacy, functional limitations, and suboptimal social support systems. As others have noted, 14 rehospitalizations in this population are related to failures in HF self-care measures and postdischarge care coordination. All CMS-approved solid-organ transplant programs (including heart transplant programs) currently are required to provide multidisciplinary care and hospital discharge planning for pre-and posttransplant patients. The physician-led team must include a care coordinator and representatives from nursing, social work, nutritional services, and pharmacology. 21 Such a care model would seem ideally suited for elderly patients with HF because several studies have shown that multidisciplinary hospital discharge education, care transition planning, and outpatient management can improve outcomes in this population. [22] [23] [24] Promoting such "spillover" effects into nontransplant candidates is not currently required by CMS for heart transplant centers. Kidney transplant centers that provide outpatient dialysis provide an interesting contrast because multidisciplinary care plans are mandated for all patients with end-stage renal disease at these centers whether or not they are listed for transplantation. 21 We speculate that many heart transplant centers apply their extensive expertise and infrastructure for HF care primarily in patients who may be transplant candidates and less so in the general population of patients with HF. If the specialized resources available at heart transplant centers are indeed focused only on the small number of transplant evaluations, an important opportunity to understand and improve postdischarge outcomes in the larger elderly HF population may be missed.
Limitations
Our findings should be considered in the context of the following study design issues and limitations. The riskstandardization models we used in this study rely on administrative data and may not fully account for all factors that affect mortality and readmission. However, the models have been extensively validated using clinical data from chart review and are supported by CMS for comparison and public reporting of hospital performance. 6, 7 Another related concern is the potential for referral to heart transplant centers for acute care hospitalization and with follow-up care provided locally, which could lead to challenges in attributing overall performance in HF outcomes to a single facility. Our focus on 30-day events was meant to minimize this possibility because these short-term outcomes are most likely to be influenced by immediate care provided during the inpatient setting. Although the CMS models and public outcomes reporting are based on this time frame, it is conceivable that a longer duration of follow-up could reveal further outcome differences between heart transplant centers and nontransplant hospitals.
The administrative data sources we used did not allow us to directly assess the quality of HF care delivered at heart transplant centers and nontransplant hospitals. Future work will need to focus on these areas because it could provide details that better explain our findings. In addition, it will be important in subsequent analyses to understand what type of resources at heart transplant centers may be available to a broad population of patients with HF. Finally, it is important to note that the results of our study cannot be extrapolated to other populations, in particular younger and potentially transplant-eligible patients with HF.
Conclusions
Heart transplant centers offer extensive and highly specialized infrastructure designed to care for the sickest and most complex patients with HF. However, in elderly Medicare patients with HF, we found little evidence that short-term outcomes are consistently better at these centers than at other nontransplant hospitals, particularly peer institutions within the same geographic area. Precise reasons for these findings are unclear but may be related to heart transplant centers specifically targeting their specialized resources to the transplant-eligible HF population. Additional studies are needed to better understand which hospital characteristics are associated with improved inpatient and postdischarge HF outcomes.
